{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:35:00Z","timestamp":1789544100864,"version":"build-2803163510"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.juro.2006.08.089","type":"journal-article","created":{"date-parts":[[2006,12,10]],"date-time":"2006-12-10T11:57:22Z","timestamp":1165751842000},"page":"17-24","source":"Crossref","is-referenced-by-count":52,"title":["Bone Health in Men Receiving Androgen Deprivation Therapy for Prostate Cancer"],"prefix":"10.1097","volume":"177","author":[{"given":"James A.","family":"Eastham","sequence":"first","affiliation":[{"name":"Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2006.08.089_bib1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2006.08.089_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ucl.2004.01.001","article-title":"Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician","volume":"31","author":"Higano","year":"2004","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.juro.2006.08.089_bib3","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.08.089_bib4","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","article-title":"Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy; recommendations for diagnosis and therapies","volume":"100","author":"Diamond","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2006.08.089_bib5","first-page":"382","article-title":"Association between androgen deprivation therapy and fracture risk: a population-based cohort study in men with non-metastatic prostate cancer","volume":"23","author":"Smith","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.juro.2006.08.089_bib6","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2006.08.089_bib7","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","article-title":"Low bone mineral density in hormone-na\u00efve men with prostate carcinoma","volume":"91","author":"Smith","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2006.08.089_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1464-410X.2003.04471.x","article-title":"Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation","volume":"92","author":"Hussain","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2006.08.089_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2006.08.089_bib10","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.08.089_bib11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2002-021036","article-title":"Differential effects of androgens and estrogens on bone turnover in normal men","volume":"88","author":"Leder","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2006.08.089_bib12","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1210\/jc.2002-021429","article-title":"Deterioration of trabecular architecture in hypogonadal men","volume":"88","author":"Benito","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2006.08.089_bib13","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jc.87.8.3656","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2006.08.089_bib14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.08.089_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00298427","article-title":"Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens","volume":"57","author":"Eriksson","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.juro.2006.08.089_bib16","series-title":"Physician\u2019s Guide to Prevention and Treatment of Osteoporosis","year":"2003"},{"key":"10.1016\/j.juro.2006.08.089_bib17","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1097\/01.ju.0000097351.48848.1f","article-title":"Management of bone loss in men with prostate cancer","volume":"170","author":"Higano","year":"2003","journal-title":"J Urol, part 2"},{"key":"10.1016\/j.juro.2006.08.089_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0093-7754(01)90233-7","article-title":"Use of markers of bone turnover for monitoring bone metastases and the response to therapy","volume":"28","author":"Lipton","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.juro.2006.08.089_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1385\/JCD:2:3:323","article-title":"Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel","volume":"2","author":"Miller","year":"1999","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.juro.2006.08.089_bib20","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z","article-title":"The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy","volume":"83","author":"Diamond","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2006.08.089_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1359\/jbmr.2000.15.2.183","article-title":"Bone matters: are density increases necessary to reduce fracture risk?","volume":"15","author":"Faulkner","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.juro.2006.08.089_bib22","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00198-004-1799-7","article-title":"Fracture risk in patients with prostate cancer on androgen deprivation therapy","volume":"16","author":"L\u00f3pez","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.juro.2006.08.089_bib23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/archinte.159.11.1215","article-title":"Vertebral fractures and mortality in older women: a prospective study","volume":"159","author":"Kado","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.juro.2006.08.089_bib24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/14656566.4.5.705","article-title":"Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease","volume":"4","author":"Dawson","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.juro.2006.08.089_bib25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42\u2032446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.juro.2006.08.089_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1677\/erc.0.0110207","article-title":"The role of bisphosphonates in breast and prostate cancers","volume":"11","author":"Brown","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.juro.2006.08.089_bib27","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.08.089_bib28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2006.08.089_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eururo.2003.10.003","article-title":"Role of bisphosphonates in prostate cancer","volume":"45","author":"Saad","year":"2004","journal-title":"Eur Urol"},{"issue":"suppl","key":"10.1016\/j.juro.2006.08.089_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","author":"Conte","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.juro.2006.08.089_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2006.08.089_bib32","series-title":"Osteonecrosis of the jaw in patients with metastatic breast cancer","author":"Van Poznak","year":"2004"},{"key":"10.1016\/j.juro.2006.08.089_bib33","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2006.08.089_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JOP.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.juro.2006.08.089_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2006.08.089_bib36","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.1995.13.9.2427","article-title":"Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study","volume":"13","author":"Robertson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2006.08.089_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J Intern Med"},{"issue":"suppl","key":"10.1016\/j.juro.2006.08.089_bib38","first-page":"S445","article-title":"Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis","volume":"19","author":"Sebaldt","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.juro.2006.08.089_bib39","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.juro.2006.08.089_bib40","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/01.ju.0000077558.48257.3d","article-title":"The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer","volume":"170","author":"Scherr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.08.089_bib41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.ju.0000165567.99142.1f","article-title":"Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism","volume":"174","author":"Ockrim","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.08.089_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0029-6465(22)02567-1","article-title":"Exercise in the prevention and treatment of osteoporosis: the role of physical therapy and nursing","volume":"36","author":"Hertel","year":"2001","journal-title":"Nurs Clin North Am"},{"key":"10.1016\/j.juro.2006.08.089_bib43","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","article-title":"Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials","volume":"293","author":"Bischoff-Ferrari","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2006.08.089_bib44","doi-asserted-by":"crossref","unstructured":"Clinical Practice Guidelines in Oncology, Prostate Cancer Version 2.2005. National Comprehensive Cancer Network 2005.","DOI":"10.6004\/jnccn.2004.0044"},{"key":"10.1016\/j.juro.2006.08.089_bib45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2006.08.089_bib46","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.juro.2006.08.089_bib47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cncr.20766","article-title":"Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy","volume":"103","author":"Tanvetyanon","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2006.08.089_bib48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.08.089_bib49","first-page":"314","article-title":"Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS)","volume":"18","author":"Higano","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.juro.2006.08.089_bib50","series-title":"Zometa\u00ae (Zoledronic Acid) Injection Prescribing Information","year":"2005"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706021719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706021719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2006.08.089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:47:56Z","timestamp":1784825276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.juro.2006.08.089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1016\/j.juro.2006.08.089"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2006.08.089","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}